183283-33-2

Upstream product

• 183283-32-1 6-(4-fluorophenyl)-3-bromoindole-1-carboxylic acid t-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 183283-31-0 6-(4-fluorophenyl)indole-1-carboxylic acid t-butyl ester 
• 147621-16-7 6-(4-fluorophenyl)-1H-indole 

Downstream Products

• 183283-57-0 6-(4-fluorophenyl)-3-{[4-(1H-2-methylimidazo[4.5-c]pyrid-1-yl)piperidin-1-yl]sulfonyl}indole-1-carboxylic acid t-butyl ester 
• 183283-64-9 6-(4-Fluoro-phenyl)-3-{4-[2-(2-methyl-imidazo[4,5-c]pyridin-1-yl)-ethyl]-piperazine-1-sulfonyl}-indole-1-carboxylic acid tert-butyl ester 
• 183283-65-0 1-(2-{4-[6-(4-Fluoro-phenyl)-1H-indole-3-sulfonyl]-piperazin-1-yl}-ethyl)-2-methyl-1H-imidazo[4,5-c]pyridine 
• 183283-58-1 6-(4-fluorophenyl)-3-{[4-(1H-2-methylimidazo[4.5-c]pyrid-1-yl)piperidin-1-yl]sulfonyl}indole 

Relevant academic research and scientific papers

Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists

Studies conducted with the goal of discovering a second-generation platelet-activating factor (PAF) antagonist have identified a novel class of potent and orally active antagonists which have high aqueous solubility and long duration of action in animal m

Indole piperazine platelet activating factor antagonists

The present invention provides compounds of formula STR1 wherein Y is >C=O or >S(O)t wherein t is 1 or 2 and the pharmaceutically acceptable salts thereof which are potent antagonists of PAF and are useful in the treatment of PAF-related disord